Acrivon Therapeutics, Inc.
ACRVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAcrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by. Valued at $74.1M, ACRV is a micro-cap name in its sector. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Market Cap
$74.1M
Beta
1.93
P/E (TTM)
—
P/E (Fwd)
-1.05
EPS (TTM)
$-1.88
EPS (Fwd)
$-1.64
ROE
-64.6%
ROA
-38.0%
Cash
$90.0M
Total Debt
$2.1M
Free CF
-$39.8M
52W Change
-17.2%
Annual Financials
Cash vs Debt
Where ACRV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ACRV finished 5.59% below its 150-day moving average ($1.79) and 5.59% below its 200-day moving average ($1.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACRV overbought or oversold?
At the October 20, 2026 close, ACRV's RSI(14) was 21.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $90.0M in cash and $2.1M in debt, ACRV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$39.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -64.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.93 means ACRV is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, ACRV has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ACRV.